FX.co ★ Nektar Therapeutics Q2 Loss Misses Estimates

Nektar Therapeutics (NKTR) reported a second-quarter loss that fell short of Wall Street's expectations.

The company posted a net loss of $52.36 million, or $0.25 per share, compared to a loss of $51.22 million, or $0.27 per share, during the same period last year.

According to Thomson Reuters, analysts had anticipated a loss of $0.20 per share. These estimates typically exclude special items.

On a positive note, the company's revenue for the quarter increased by 14.6%, reaching $23.49 million, up from $20.50 million the previous year.

Summary of Nektar Therapeutics' earnings (GAAP):

- Earnings (Q2): -$52.36 million vs. -$51.22 million last year.

- EPS (Q2): -$0.25 vs. -$0.27 last year.

- Revenue (Q2): $23.49 million vs. $20.50 million last year.